Florbetapir F18淀粉样蛋白PET对认知障碍患者的增量诊断价值
多中心研究纳入228例认知障碍患者,在常规评估基础上加做氟比他班F18淀粉样蛋白PET,结果示诊断改变在既往AD诊断且扫描阴性者中占79%,在非AD诊断且扫描阳性者中占53%,AD诊断信心在阳性者中提高15.2%、阴性者中降低29.9%,并显著影响药物治疗。
要点
- 淀粉样蛋白PET可显著改变认知障碍患者的诊断和诊断信心。
- 扫描结果影响乙酰胆碱酯酶抑制剂和美金刚的启用或停用。
- 对健康结局的影响(如患病率和死亡率)尚待评估。
核心结论
- 在常规评估基础上加做氟比他班F18淀粉样蛋白PET对认知障碍患者的诊断、诊断信心和药物治疗有显著影响。
- 对健康结局如患病率和死亡率的影响仍需评估。
研究设计与样本
- 多中心研究,纳入意大利伦巴第东部18个AD评估单位的228例连续认知障碍成人,扫描前AD诊断信心为15%至85%。
主要发现
- 228例中男性107例(46%),平均(SD)年龄70.5(7)岁。
- 既往AD诊断且淀粉样蛋白扫描阴性者中46例(79%)发生诊断改变(P < .001)。
- 非AD诊断且淀粉样蛋白扫描阳性者中16例(53%)发生诊断改变(P < .001)。
- AD诊断信心在淀粉样蛋白阳性者中提高15.2%(P < .001;Cohen d = 1.04),在阴性者中降低29.9%(P < .001;d = -1.19)。
- 阳性扫描且既往未用相关药物者中61例(65.6%)启用乙酰胆碱酯酶抑制剂和美金刚盐酸盐,阴性扫描且正在用药者中6例(33.3%)停药(P < .001)。
临床怎么用
- 对诊断信心在15%至85%的认知障碍患者,可考虑加做淀粉样蛋白PET以辅助诊断分型。
- PET结果可支持或反对AD诊断,并影响胆碱酯酶抑制剂和美金刚的启用或停用决策。
局限性
- 研究未评估对健康结局(如患病率和死亡率)的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected in vivo with positron emission tomography (PET) ligands. Although amyloid PET has clearly demonstrated analytical validity, its clinical utility is debated. OBJECTIVE: To evaluate the incremental diagnostic value of amyloid PET with florbetapir F 18 in addition to the routine clinical diagnostic assessment of patients evaluated for cognitive impairment. DESIGN, SETTING, AND PARTICIPANTS: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study is a multicenter study involving 18 AD evaluation units from eastern Lombardy, Northern Italy, 228 consecutive adults with cognitive impairment were evaluated for AD and other causes of cognitive decline, with a prescan diagnostic confidence of AD between 15% and 85%. Participants underwent routine clinical and instrumental diagnostic assessment. A prescan diagnosis was made, diagnostic confidence was estimated, and drug treatment was provided. At the time of this workup, an amyloid PET/computed tomographic scan was performed, and the result was communicated to physicians after workup completion. Physicians were asked to review the diagnosis, diagnostic confidence, and treatment after the scan. The study was conducted from August 5, 2013, to December 31, 2014. MAIN OUTCOMES AND MEASURES: Primary outcomes were prescan to postscan changes of diagnosis, diagnostic confidence, and treatment. RESULTS: Of the 228 participants, 107 (46%) were male; mean (SD) age was 70.5 (7) years. Diagnostic change occurred in 46 patients (79%) having both a previous diagnosis of AD and an amyloid-negative scan (P < .001) and in 16 (53%) of those with non-AD diagnoses and an amyloid-positive scan (P < .001). Diagnostic confidence in AD diagnosis increased by 15.2% in amyloid-positive (P < .001; effect size Cohen d = 1.04) and decreased by 29.9% in amyloid-negative (P < .001; d = -1.19) scans. Acetylcholinesterase inhibitors and memantine hydrochloride were introduced in 61 (65.6%) patients with positive scan results who had not previously received those drugs, and the use of the drugs was discontinued in 6 (33.3%) patients with negative scan results who were receiving those drugs (P < .001). CONCLUSIONS AND RELEVANCE: Amyloid PET in addition to routine assessment in patients with cognitive impairment has a significant effect on diagnosis, diagnostic confidence, and drug treatment. The effect on health outcomes, such as morbidity and mortality, remains to be assessed.
引用
- Boccardi M, Altomare D, Ferrari C, et al. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol. 2016. PMID: 27802513. doi:10.1001/jamaneurol.2016.3751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。